Prosecution Insights
Last updated: November 20, 2026
Application No. 17/783,455

METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY A PHYTOPATHOGENIC MICROORGANISM OF THE GENUS MACROPHOMINA SPP.

Non-Final OA §103§DOUBLEPATENT
Filed
Jun 08, 2022
Priority
Dec 10, 2019 — EU 19214692.6 +1 more
Examiner
FETTEROLF, BRANDON J
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Syngenta AG
OA Round
3 (Non-Final)
51%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
118 granted / 232 resolved
-9.1% vs TC avg
Strong +20% interview lift
Without
With
+20.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
69 currently pending
Career history
291
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
28.6%
-11.4% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
28.9%
-11.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 232 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/31/2026 has been entered. Claims 1 and 8-20 are currently pending an under consideration. The following species consistent the reply filed on 8/08/2025 is under consideration: PNG media_image1.png 104 221 media_image1.png Greyscale , wherein A is 2-trifluoromethyl-pyrid-3-yl, and R11 and R12 are both chloro. Compact Prosecution A telephone call was made to Applicants representative, Rong Yang, on 9/29/2026 to amend the claims to remove “preventing” and delete compounds of formula’s (Ia) and (1b) to put the application in condition for allowance. However, Applicants representative requested a Non-Final Office Action. Information Disclosure Statement The information disclosure statement filed on 8/31/2026 is acknowledged and has been considered except where lined through. Claim Interpretation Claim 1 recites a method of controlling or preventing infestation of a plant by macrophomina spp comprising applying a compound of formula (I). Thus, the instant claims appear to encompass two different “populations” or times in which the compound of formula (I) could be applied to the plant. For example, “controlling” insinuates that the plant has the infestation by macrophomina spp prior to application of the compound of formula (I) which appears to be consistent with the examples within the specification. “Preventing” the infestation reasonably conveys that the plant has not yet gotten the infestation at the time of application of compound of Formula (I). For examination purposes, “preventing” reads on application of compound I to any plant that has not yet been infested with macrophomina spp. Response to Amendment The declaration under 37 CFR 1.132 filed 8/31/2026 is insufficient to overcome the rejection of claims 1 and 8-15 as being obvious based upon the prior art combination as set forth in the last Office action because: while the declaration provides direct, controlled, and statistically analyzed evidence of an unexpected technical effect for using Compound 1 to control M. phaseolina in plants the claims appear to encompass two different populations. As noted above, Claim 1 recites a method of controlling or preventing infestation of a plant by macrophomina spp comprising applying a compound of formula (I). Thus, the instant claims appear to encompass two different “populations” or times in which the compound of formula (I) could be applied to the plant. For example, “controlling” insinuates that the plant has the infestation by macrophomina spp prior to application of the compound of formula (I) which appears to be consistent with the examples within the specification. “Preventing” the infestation reasonably conveys that the plant has not yet gotten the infestation at the time of application of compound of Formula (I). For examination purposes, “preventing” reads on application of compound I to any plant that has not yet been infested with macrophomina spp. In the instant case, as noted in the prior art rejections set forth below, the claimed compounds have a broad range of activity against a variety of pathogenic microorganisms. For example, Bayer teaches that the compounds are useful for treating plants including, but not limited to, strawberries and further teaches the compounds are useful for treating phytopathogenic fungi including fungal diseases on roots and stem bases caused by charcoal rot (Macrophomina phaseolina). Moreover, Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in a number of cell lines including, but not limited to, Alternaria alternata, Botrytis cinerea and Rhizoctonia solani, (examples A-K). Considering that Garrido et al. discuss that fungal pathogens causing strawberry leaf disease includes, but is not limited to, Alternaria alternata, Macrophomina phaseolina and Rhizoctonia solani, it would be prima facia obvious to treat strawberries since the compounds have been shown to be effective against Alternaria alternata, Rhizoctonia solani. Thus, this would read on prevention since the claims do not require Macrophomina phaseolina. It should be noted that: The reason or motivation to modify the reference may often suggest what the inventor has done, but for a different purpose or to solve a different problem. It is not necessary that the prior art suggest the combination to achieve the same advantage or result discovered by applicant. See, e.g., In re Kahn, 441 F.3d 977, 987, 78 USPQ2d 1329, 1336 (Fed. Cir. 2006) See MPEP 2144 (IV). Objections upon re-consideration: Claim Objections Claim 1 is objected to because of the following informalities: Regarding claim 1, claim 1 recites compounds having the formula’s Ia and Ib: PNG media_image2.png 158 424 media_image2.png Greyscale . However, the claim does not define any of the variables. While the examiner acknowledges that the claims also recites that the compound of formula (Ia) is a compound of Formula (Ic), wherein the variables of Ic are defined, the chemical formula’s of Ia and Ib also contain variables which are not defined and makes the claims confusing. Appropriate correction is required. Rejections Maintained, but Amended in view of Applicants Amendments: Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1 and 8-20 remain rejected under 35 U.S.C. 103 as being unpatentable over Bayer Cropscience (WO2016/066644A1, 2016-05-06, IDS) referred to herein as Bayer in view of Garrido et al. (Genes, Genomes and Genomics 2011; 5(Special Issue 1): 24-39) and Syngenta Participations, AG (WO2015/003951A1, 2015-01-15, IDS) referred to herein as Syngenta. Bayer teaches the use of N-(Phenylcycloalkyl)carboxamides or N-(Phenylcycloalkyl)thiocarboxamides for the control of phytopathogenic microorganisms in agriculture, wherein a compound of formula (I) is applied to the phytopathogenic microorganisms, their habitat, the plant, the seed thereof, plant parts, plant propagation material or soil on which the plants are grown or intended to be grown in an effective amount (abstract). With regards to the compound of formula (I), Bayer teaches compounds of formula I have the general structure PNG media_image3.png 231 319 media_image3.png Greyscale (page 90). In particular, Bayer teach a specific compound having the general structure of formula I, wherein B is cBu (e.g. cyclobutyl), X1 is H, X2 is H, X3 is Cl, X4 is H, X5 is Cl, Z1 is H, Z2 is H, T is O and A is 2-(trifluoromethyl)-pyridinyl-2-yl in the Cis orientation (cmpd 179, page 100). With regards to the plants, Bayer teaches that useful plants include, but are not limited to, strawberries (page 73). With regards to the phytopathogenic microorganism, Bayer teaches that phytopathogenic microorganisms, in particular phytopathogenic fungi include fungal diseases on roots and stem bases caused by charcoal rot (Macrophomina phaseolina) (page 77, lines 8-10). With regards to the application, Bayer teach that the application rates of each single active ingredient is generally between 0.001 and 15 g per kilogram of seed, preferably between 0.01 and 5 g per kilogram of seed (page 86, lines 20-21). Moreover, Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in a number of cell lines including, but not limited to, Alternaria alternata, Botrytis cinerea and Rhizoctonia solani, (examples A-K). Bayer does not specifically select strawberries as the plant, Macrophomina phaseolina as the fungal disease or compound 179 as the compound for the treatment or prevention of fulfil pathogen infestation. Moreover, Bayer does not specifically teach that compound 179 which is in the cis orientation has the (S,S) stereo configuration, wherein if the composition also contains the (R,R) stereo-confirmation, the weight ratio of the (S,S) stereo configuration to the (R,R) stereo configuration is greater than about 1:1. Lastly, Bayer does not specifically teach application at a rate of about 1 to 500 g/ha. Garrido et al. discuss the main leaf, fruit, crown and root strawberry fungal diseases. With regards to the leaf diseases, the reference teaches that fungal pathogens causing leaf disease includes, but is not limited to, Alternaria alternata, Macrophomina phaseolina and Rhizoctonia solani (Table 1). With regards to the fruit disease, the reference teaches fungal pathogens causing fruit diseases includes, but is not limited to, Botrytis cinerea and Rhizoctonia solani (Table 2). With regards to the crown and root diseases, the reference teaches fungal pathogens causing root and crowns diseases include, but are not limited to, Macrophomina phaseolina and Rhizoctonia solani (Table 3). Syngenta teaches cis substituted 4-membered carboxamides useful as nematicides having the generic structure PNG media_image4.png 84 165 media_image4.png Greyscale (page 1, lines 6-10). Syngenta further teaches that a potential side product in the synthesis of the compound of formula I is the enantiomer of the compound formula I, e.g. compounds of formula (1aa): PNG media_image5.png 151 365 media_image5.png Greyscale , wherein in compositions comprising both the compound of formula (I) and formula (Iaa), the ratio of the compound of formula (I) to its enantiomer (the compound of formula (Iaa)) must be greater than 1:1 (pages 2-3, lines 21 to line 10). Specifically, the WO document teaches a compound having the structure PNG media_image6.png 115 244 media_image6.png Greyscale wherein Y is CH2, R1 is H, R13 and R14 are 2-Cl and 4-Cl respectively, R15 is H and A is PNG media_image7.png 96 108 media_image7.png Greyscale (P.15, 61.1) which reads on the elected species (Table P and Table 61). With regards to the nematocidal activity, the WO document teaches that the compound are useful for controlling or destroying pests such as insects and/or fungi which occur on plants such as fruit plants, wherein the compounds of formula I have a very advantageous spectrum of activities for protecting against attack and damage by fungi and nematodes (page 55, lines 19-36). Moreover, the WO document teaches that the compounds of the formula I are also suitable for protection of plant propagation material such a seeds, fruit, tubers or nursery plants wherein the compound is treated prior to planting (page 61, lines 13-15). With regards to the plant, the WO document teaches that suitable target plants include strawberries (page 62, lines 3-5). Moreover, Syngenta teaches that compound 61.1, as a preventative, showed a greater than 80% reduction in Meloidogyne spp. (Root-knot nematode) galling (page 135, lines 14-38). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to modify the composition taught by Bayer to having a ratio of greater than 1:1 of the (S,S) stereo configuration to the (R,R) stereo configuration in view of the teachings of Syngenta. One of ordinary skill in the art would have been motivated to make such a modification, with a reasonable expectation of success, because: - Both Bayer and Syngenta teach the same compound, wherein Syngenta teaches that a potential side product in the synthesis of the compound of formula I is the enantiomer of the compound formula I, e.g. compounds of formula (1aa): PNG media_image5.png 151 365 media_image5.png Greyscale , wherein in compositions comprising both the compound of formula (I) and formula (Iaa), the ratio of the compound of formula (I) to its enantiomer (the compound of formula (Iaa)) must be greater than 1:1 (pages 2-3, lines 21 to line 10 Additionally, it would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to apply compound 179 to strawberries as taught by Bayer in view of the teachings of Garrido et al. One of ordinary skill in the art would have been motivated to make such a selection, with a reasonable expectation of success, because: - Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in numerous in vitro cell assays containing fungal pathogens such as Alternaria alternata, Botrytis cinerea and Rhizoctonia solani; and -Garrido et al. teaches that all of these fungal pathogens cause either leaf, fruit or crown and root disease. Moreover, it would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to optimize the application rate of compound 179 as taught by Bayer to the plants. One of ordinary skill in the art would have been motivated to make such a optimization, with a reasonable expectation of success, because: - Bayer teach that the application rates of each single active ingredient is generally between 0.001 and 15 g per kilogram of seed, preferably between 0.01 and 5 g per kilogram of seed. Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) NOTE: The above portion of the rejection addresses the prevention aspect of the claims since prevention does not require that the plant actually have the claimed fungal pathogen. In response to this rejection, Applicants maintain the rebuttal of record. Since the Examiner has responded previously to the arguments in the Final office action and has addressed the declaration set forth above, the rejections are maintained for the reasons of record. Claim(s) 1 and 8-20 remain rejected under 35 U.S.C. 103 as being unpatentable over Syngenta Participations, AG (WO2015/003951A1, 2015-01-15, IDS) referred to herein as Syngenta in view of Desaeger, Johan. 2019.”Meloidogyn Hapla, the Northern Root-Knot Nematode, in Florida Strawberries and Associated Double-Cropped Vegetables: ENY-070 IN1224, 10 2018”. (Note: the below rejection address the prevention aspect encompassed by the claims as described above which does not require the plant to be infected with the pathogenic microorganism). Syngenta teaches cis substituted 4-membered carboxamides useful as nematicides having the generic structure PNG media_image4.png 84 165 media_image4.png Greyscale (page 1, lines 6-10). Syngenta further teaches that a potential side product in the synthesis of the compound of formula I is the enantiomer of the compound formula I, e.g. compounds of formula (1aa): PNG media_image5.png 151 365 media_image5.png Greyscale , wherein in compositions comprising both the compound of formula (I) and formula (Iaa), the ratio of the compound of formula (I) to its enantiomer (the compound of formula (Iaa)) must be greater than 1:1 (pages 2-3, lines 21 to line 10). Specifically, the WO document teaches a compound having the structure PNG media_image6.png 115 244 media_image6.png Greyscale wherein Y is CH2, R1 is H, R13 and R14 are 2-Cl and 4-Cl respectively, R15 is H and A is PNG media_image7.png 96 108 media_image7.png Greyscale (P.15, 61.1) which reads on the elected species (Table P and Table 61). With regards to the nematocidal activity, the WO document teaches that the compound are useful for controlling or destroying pests such as insects and/or fungi which occur on plants such as fruit plants, wherein the compounds of formula I have a very advantageous spectrum of activities for protecting against attach and damage by fungi and nematodes (page 55, lines 19-36). Moreover, the WO document teaches that the compounds of the formula I are also suitable for protection of plant propagation material such a seeds, fruit, tubers or nursery plants wherein the compound is treated prior to planting (page 61, lines 13-15). With regards to the plant, the WO document teaches that suitable target plants include strawberries (page 62, lines 3-5). With regards to the application, Syngenta teaches that typical rates of application per hectare is generally 1 to 2000 g of active ingredient per hectare, in particular 10 to 1000 g/ha, preferably 10 to 600 g/ha, such as 50 to 300 g/ha (page 61, lines 11-12). Moreover, Syngenta teaches that compound 61.1, as a preventative, showed a greater than 80% reduction in Meloidogyne spp. (Root-knot nematode) galling (page 135, lines 14-38). Syngenta does not specifically teach specifically select compound 61.1 for application to strawberries. Desaeger teaches that root-knot nematodes (Meloidogyne spp.) (RKN) are the most common and destructive plant-parasitic nematodes globally, wherein while it has not been considered a major problem in Florida yet diagnostic studies conducted recently have confirmed a wider distribution of RKN than previously thought (Importance, History and Distribution). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to have applied 61.1 as taught by Syngenta to strawberries for the prevention or treatment of root-knot nematodes (Meloidogyne spp.) in view of the teachings of Desaeger. One of ordinary skill in the art would have been motivated to make such a modification, with a reasonable expectation of success, because: - Syngenta teaches that compound 61.1, as a preventative, showed a greater than 80% reduction in Meloidogyne spp. (Root-knot nematode) galling; and -Desaeger teaches that while Root-Knot nematode (Meloidogyne spp.) has not been considered a major problem in Florida yet diagnostic studies conducted recently have confirmed a wider distribution of RKN than previously thought. In response to this rejection, Applicants maintain the rebuttal of record. Since the Examiner has responded previously to the arguments in the Final office action and has addressed the declaration set forth above, the rejections are maintained for the reasons of record. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1 and 8-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 9,867,371 in view of Desaeger, Johan. 2019.”Meloidogyn Hapla, the Northern Root-Knot Nematode, in Florida Strawberries and Associated Double-Cropped Vegtables: ENY-070 IN1224, 10 2018”. The US Patent claims a method of controlling pests in the soil, the method comprising, applying to the soil a composition comprising PNG media_image8.png 114 228 media_image8.png Greyscale , wherein the pest is a nematode. The US Patent does not specifically claim administering the compound to a strawberry plant. Nor does the US Patent claim the application rate of 1 to 500g/ha. Desaeger teaches that root-knot nematodes (Meloidogyne spp.) (RKN) are the most common and destructive plant-parasitic nematodes globally, wherein while it has not been considered a major problem in Florida yet diagnostic studies conducted recently have confirmed a wider distribution of RKN than previously thought (Importance, History and Distribution). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to have applied the compound claimed by the US Patent to strawberries for the prevention or treatment of root-knot nematodes (Meloidogyne spp.) in view of the teachings of Desaeger. One of ordinary skill in the art would have been motivated to make such a modification, with a reasonable expectation of success, because: - -Desaeger teaches that while Root-Knot nematode (Meloidogyne spp.) has not been considered a major problem in Florida yet diagnostic studies conducted recently have confirmed a wider distribution of RKN than previously thought. Moreover, it would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to optimize the application rate of the compound claimed in the US Patent to the plants. One of ordinary skill in the art would have been motivated to make such a optimization, with a reasonable expectation of success, because: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) In response to this rejection, Applicants maintain the rebuttal of record. Since the Examiner has responded previously to the arguments in the Final office action and has addressed the declaration set forth above, the rejections are maintained for the reasons of record. Claims 1 and 8-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 11,053,201B2 to Hone and Jones (2021-07-06) in view of Garrido et al. (Genes, Genomes and Genomics 2011; 5(Special Issue 1): 24-39). The US Patent claims a method of controlling crops of useful plants against damages caused by nematode pests or fungi and protecting plants from propagation material against damages caused by fungi, comprising treating the plants with a composition comprising PNG media_image8.png 114 228 media_image8.png Greyscale . The US Patent does not specifically claim administering the compound to a strawberry plant. Nor does the US Patent claim the application rate of 1 to 500g/ha Garrido et al. discuss the main leaf, fruit, crown and root strawberry fungal diseases. With regards to the leaf diseases, the reference teaches that fungal pathogens causing leaf disease includes, but is not limited to, Alternaria alternata, Macrophomina phaseolina and Rhizoctonia solani (Table 1). With regards to the fruit disease, the reference teaches fungal pathogens causing fruit diseases includes, but is not limited to, Botrytis cinerea and Rhizoctonia solani (Table 2). With regards to the crown and root diseases, the reference teaches fungal pathogens causing root and crowns diseases include, but are not limited to, Macrophomina phaseolina and Rhizoctonia solani (Table 3). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to modify the method claimed by the US Patent to treat strawberries as a preventative against fungal damage in view of the teachings of Garrido et al. One of ordinary skill in the art would have been motivated to make such a modification, with a reasonable expectation of success, because: - Garrido et al. teaches that numerous fungal pathogens cause either leaf, fruit or crown and root disease. Moreover, it would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to optimize the application rate of the compound claimed in the US Patent to the plants. One of ordinary skill in the art would have been motivated to make such a optimization, with a reasonable expectation of success, because: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) NOTE: The above portion of the rejection addresses the prevention aspect of the claims since prevention does not require that the plant actually have the claimed fungal pathogen. In response to this rejection, Applicants maintain the rebuttal of record. Since the Examiner has responded previously to the arguments in the Final office action and has addressed the declaration set forth above, the rejections are maintained for the reasons of record. Claims 1 and 8-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 8 and 11 of U.S. Patent No. 12446582B2 to Kenneth Mckee (2025-10-21) in view of Bayer Cropscience (WO2016/066644A1, 2016-05-06, IDS) and Garrido et al. (Genes, Genomes and Genomics 2011; 5(Special Issue 1): 24-39). The US patent claims a method of controlling or preventing infestation of cereal plants by Fusarium pseudograminearum comprising applying to a crop of plants, the locus thereof, or seed thereof a compound of the formula PNG media_image8.png 114 228 media_image8.png Greyscale . The US Patent does not claim that the method is used to prevent infestation of strawberry plants by Macrophomina phaseolina. Nor does the US Patent claim an application rate of 1 to 500g/ha. Bayer teaches the use of N-(Phenylcycloalkyl)carboxamides or N-(Phenylcycloalkyl)thiocarboxamides for the control of phytopathogenic microorganisms in agriculture, wherein a compound of formula (I) is applied to the phytopathogenic microorganisms, their habitat, the plant, the seed thereof, plant parts, plant propagation material or soil on which the plants are grown or intended to be grown in an effective amount (abstract). With regards to the compound of formula (I), Bayer teaches compounds of formula I have the general structure PNG media_image3.png 231 319 media_image3.png Greyscale (page 90). In particular, Bayer teach a specific compound having the general structure of formula I, wherein B is cBu (e.g. cyclobutyl), X1 is H, X2 is H, X3 is Cl, X4 is H, X5 is Cl, Z1 is H, Z2 is H, T is O and A is 2-(trifluoromethyl)-pyridinyl-2-yl in the Cis orientation which is identical to the application claimed in both the instant application and the US Patent (cmpd 179, page 100). With regards to the plants, Bayer teaches that useful plants include, but are not limited to, strawberries (page 73). With regards to the phytopathogenic microorganism, Bayer teaches that phytopathogenic microorganisms, in particular phytopathogenic fungi include fungal diseases on roots and stem bases caused by charcoal rot (Macrophomina phaseolina) (page 77, lines 8-10). Moreover, Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in a number of cell lines including, but not limited to, Alternaria alternata, Botrytis cinerea and Rhizoctonia solani, (examples A-K). Garrido et al. discuss the main leaf, fruit, crown and root strawberry fungal diseases. With regards to the leaf diseases, the reference teaches that fungal pathogens causing leaf disease includes, but is not limited to, Alternaria alternata, Macrophomina phaseolina and Rhizoctonia solani (Table 1). With regards to the fruit disease, the reference teaches fungal pathogens causing fruit diseases includes, but is not limited to, Botrytis cinerea and Rhizoctonia solani (Table 2). With regards to the crown and root diseases, the reference teaches fungal pathogens causing root and crowns diseases include, but are not limited to, Macrophomina phaseolina and Rhizoctonia solani (Table 3). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to modify the method claimed in the US Patent so as to apply the compound to strawberries in view of the teachings of Bayer and Garrido et al. One of ordinary skill in the art would have been motivated to make such a modification, with a reasonable expectation of success, because: - Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in numerous in vitro cell assays containing fungal pathogens such as Alternaria alternata, Botrytis cinerea and Rhizoctonia solani; and -Garrido et al. teaches that all of these fungal pathogens cause either leaf, fruit or crown and root disease. Moreover, it would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to optimize the application rate of the compound claimed in the US Patent to the plants. One of ordinary skill in the art would have been motivated to make such a optimization, with a reasonable expectation of success, because: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) NOTE: The above portion of the rejection addresses the prevention aspect of the claims since prevention does not require that the plant actually have the claimed fungal pathogen. In response to this rejection, Applicants maintain the rebuttal of record. Since the Examiner has responded previously to the arguments in the Final office action and has addressed the declaration set forth above, the rejections are maintained for the reasons of record. Claims 1 and 8-20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1, 8-11 and 15-19 of copending Application No. 17783859 or over at least claims 36-46 of copending application 17425119 in view of Bayer Cropscience (WO2016/066644A1, 2016-05-06, IDS) and Garrido et al. (Genes, Genomes and Genomics 2011; 5(Special Issue 1): 24-39). All of the copending application listed above claim a method of controlling or preventing an infestation within a plants by a particular microorganism comprising applying to a crop of plants, the locus thereof, or seed thereof a compound of the formula PNG media_image8.png 114 228 media_image8.png Greyscale . For example, the 17783859 application claims that the plant is a peanut plant and the microorganism is Cercospora. The 17425119 application claims that the plant is corn and the microorganism is Fusarium graminearum. Moroever, both the ‘859 and the ‘119 application claims an application rate of 1 to 500 g/ha. The claims of the copending applications differ from the instant application in that the method is used to prevent infestation of strawberry plants by Macrophomina phaseolina. Bayer teaches the use of N-(Phenylcycloalkyl)carboxamides or N-(Phenylcycloalkyl)thiocarboxamides for the control of phytopathogenic microorganisms in agriculture, wherein a compound of formula (I) is applied to the phytopathogenic microorganisms, their habitat, the plant, the seed thereof, plant parts, plant propagation material or soil on which the plants are grown or intended to be grown in an effective amount (abstract). With regards to the compound of formula (I), Bayer teaches compounds of formula I have the general structure PNG media_image3.png 231 319 media_image3.png Greyscale (page 90). In particular, Bayer teach a specific compound having the general structure of formula I, wherein B is cBu (e.g. cyclobutyl), X1 is H, X2 is H, X3 is Cl, X4 is H, X5 is Cl, Z1 is H, Z2 is H, T is O and A is 2-(trifluoromethyl)-pyridinyl-2-yl in the Cis orientation which is identical to the application claimed in both the instant application and the US Patent (cmpd 179, page 100). With regards to the plants, Bayer teaches that useful plants include, but are not limited to, strawberries (page 73). With regards to the phytopathogenic microorganism, Bayer teaches that phytopathogenic microorganisms, in particular phytopathogenic fungi include fungal diseases on roots and stem bases caused by charcoal rot (Macrophomina phaseolina) (page 77, lines 8-10). Moreover, Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in a number of cell lines including, but not limited to, Alternaria alternata, Botrytis cinerea and Rhizoctonia solani, (examples A-K). Garrido et al. discuss the main leaf, fruit, crown and root strawberry fungal diseases. With regards to the leaf diseases, the reference teaches that fungal pathogens causing leaf disease includes, but is not limited to, Alternaria alternata, Macrophomina phaseolina and Rhizoctonia solani (Table 1). With regards to the fruit disease, the reference teaches fungal pathogens causing fruit diseases includes, but is not limited to, Botrytis cinerea and Rhizoctonia solani (Table 2). With regards to the crown and root diseases, the reference teaches fungal pathogens causing root and crowns diseases include, but are not limited to, Macrophomina phaseolina and Rhizoctonia solani (Table 3). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to modify the method claimed in the copending applications so as to apply the compound to strawberries in view of the teachings of Bayer and Garrido et al. One of ordinary skill in the art would have been motivated to make such a modification, with a reasonable expectation of success, because: - Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in numerous in vitro cell assays containing fungal pathogens such as Alternaria alternata, Botrytis cinerea and Rhizoctonia solani; and -Garrido et al. teaches that all of these fungal pathogens cause either leaf, fruit or crown and root disease. NOTE: The above portion of the rejection addresses the prevention aspect of the claims since prevention does not require that the plant actually have the claimed fungal pathogen. This is a provisional nonstatutory double patenting rejection. In response to this rejection, Applicants maintain the rebuttal of record. Since the Examiner has responded previously to the arguments in the Final office action and has addressed the declaration set forth above, the rejections are maintained for the reasons of record. Claims 1 and 8-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over at least claim 1 of U.S. Patent No. 12,575,569 or at least claim 1 of US Patent No 12,317,897 or at least claim 1 and 14 of US12,740,560 or at least claim 1 and 12 of US Patent 12,745,771 in view of Bayer Cropscience (WO2016/066644A1, 2016-05-06, IDS) and Garrido et al. (Genes, Genomes and Genomics 2011; 5(Special Issue 1): 24-39). US Patent No. 12,575,569 claims a method of controlling or preventing an infestation within a plants by a particular microorganism comprising applying to a crop of plants, the locus thereof, or seed thereof a compound of the formula PNG media_image8.png 114 228 media_image8.png Greyscale wherein the plant is a rice plant and the microorganism is Gibberella fujikuroi. US Patent No 12,317,897 claims a method of controlling or preventing an infestation within a plants by a particular microorganism comprising applying to a crop of plants, the locus thereof, or seed thereof a compound of the formula PNG media_image8.png 114 228 media_image8.png Greyscale wherein the plant is tomato and the microorganism is from Alternaria solani. US Patent 12745771 claims a method of controlling or preventing infestation of soybean plants by phytopathogenic microorganisms of the family Corynesporascaceae, comprising: applying to a soybean seed a seed treatment composition comprising: a compound of formula (Ic) PNG media_image8.png 114 228 media_image8.png Greyscale and an enantiomer of the compound of formula (Ic); wherein the ratio of the compound of formula (Ic) to the enantiomer is greater than 4:1 in the seed treatment composition. Moreover, the US Patent claims an application rate of 1 to 500g/ha. US Patent 12740560 claims a method of controlling or preventing infestation of a banana plant by phytopathogenic microorganism Pseudocercospora fijiensis, comprising applying to a crop of the banana plant, a locus thereof, or a propagation material thereof, a composition comprising an effective amount of a cis-configured compound according to formula (Ic) PNG media_image8.png 114 228 media_image8.png Greyscale ; and wherein the ratio of the compound of formula (Ic) to its corresponding cis-enantiomer is greater than 4:1. Moreover, the US Patent claims an application rate of 50 to 300 g/ha. The claims of US Patents differ from the instant application in that the method is used to prevent infestation of strawberry plants by Macrophomina phaseolina. Nor do the US Patents claim an application rate of 1 to 500 g/ha. Bayer teaches the use of N-(Phenylcycloalkyl)carboxamides or N-(Phenylcycloalkyl)thiocarboxamides for the control of phytopathogenic microorganisms in agriculture, wherein a compound of formula (I) is applied to the phytopathogenic microorganisms, their habitat, the plant, the seed thereof, plant parts, plant propagation material or soil on which the plants are grown or intended to be grown in an effective amount (abstract). With regards to the compound of formula (I), Bayer teaches compounds of formula I have the general structure PNG media_image3.png 231 319 media_image3.png Greyscale (page 90). In particular, Bayer teach a specific compound having the general structure of formula I, wherein B is cBu (e.g. cyclobutyl), X1 is H, X2 is H, X3 is Cl, X4 is H, X5 is Cl, Z1 is H, Z2 is H, T is O and A is 2-(trifluoromethyl)-pyridinyl-2-yl in the Cis orientation which is identical to the application claimed in both the instant application and the US Patent (cmpd 179, page 100). With regards to the plants, Bayer teaches that useful plants include, but are not limited to, strawberries (page 73). With regards to the phytopathogenic microorganism, Bayer teaches that phytopathogenic microorganisms, in particular phytopathogenic fungi include fungal diseases on roots and stem bases caused by charcoal rot (Macrophomina phaseolina) (page 77, lines 8-10). Moreover, Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in a number of cell lines including, but not limited to, Alternaria alternata, Botrytis cinerea and Rhizoctonia solani, (examples A-K). Garrido et al. discuss the main leaf, fruit, crown and root strawberry fungal diseases. With regards to the leaf diseases, the reference teaches that fungal pathogens causing leaf disease includes, but is not limited to, Alternaria alternata, Macrophomina phaseolina and Rhizoctonia solani (Table 1). With regards to the fruit disease, the reference teaches fungal pathogens causing fruit diseases includes, but is not limited to, Botrytis cinerea and Rhizoctonia solani (Table 2). With regards to the crown and root diseases, the reference teaches fungal pathogens causing root and crowns diseases include, but are not limited to, Macrophomina phaseolina and Rhizoctonia solani (Table 3). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to modify the method claimed in the US Patents so as to apply the compound to strawberries in view of the teachings of Bayer and Garrido et al. One of ordinary skill in the art would have been motivated to make such a modification, with a reasonable expectation of success, because: - Bayer teaches a number of in vitro test cell tests wherein compound 179 showed efficacy in numerous in vitro cell assays containing fungal pathogens such as Alternaria alternata, Botrytis cinerea and Rhizoctonia solani; and -Garrido et al. teaches that all of these fungal pathogens cause either leaf, fruit or crown and root disease. Moreover, it would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to optimize the application rate of the compound claimed in the US Patents to the plants. One of ordinary skill in the art would have been motivated to make such a optimization, with a reasonable expectation of success, because: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) NOTE: The above portion of the rejection addresses the prevention aspect of the claims since prevention does not require that the plant actually have the claimed fungal pathogen. In response to this rejection, Applicants maintain the rebuttal of record. Since the Examiner has responded previously to the arguments in the Final office action and has addressed the declaration set forth above, the rejections are maintained for the reasons of record. Conclusion Therefore, No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRANDON J FETTEROLF whose telephone number is (571)272-2919. The examiner can normally be reached M-F 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. BRANDON J. FETTEROLF, PHD Primary Patent Examiner Art Unit 1626 /BRANDON J FETTEROLF/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jun 08, 2022
Application Filed
Dec 12, 2025
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Mar 12, 2026
Response Filed
Mar 31, 2026
Final Rejection mailed — §103, §DOUBLEPATENT
Aug 31, 2026
Response after Non-Final Action
Aug 31, 2026
Request for Continued Examination
Sep 01, 2026
Response after Non-Final Action
Nov 04, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788771
MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER
3y 4m to grant Granted Nov 10, 2026
Patent 12788757
SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE
2y 10m to grant Granted Nov 10, 2026
Patent 12780840
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
3y 7m to grant Granted Nov 03, 2026
Patent 12774270
DESIGN, SYNTHESIS AND MECHANISMS OF ANTICANCER ACTIVITY OF NEW ACETYLATED 5-AMINOSALICYLATE-THIAZOLINONE HYBRID DERIVATIVES
3y 4m to grant Granted Oct 27, 2026
Patent 12774278
THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF
3y 0m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
51%
Grant Probability
71%
With Interview (+20.1%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 232 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month